ORIC Pharmaceuticals IPO

4/23/2020

IPO

$120,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $50.0 million to fund the development of ORIC-101, including our two ongoing Phase 1b trials of ORIC-101 in combination with (1) enzalutamide in prostate cancer and (2) nab-paclitaxel in advanced or metastatic solid tumors, and the planned Phase 1b/2 dose expansion portion of such trials; approximately $10.0 million to fund our development of ORIC-533; and the remaining amounts to fund our development of other research and development activities, as well as for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

240 E. Grand Ave. 2nd Floor
South San Francisco, CA 94080
USA

ORIC Pharmaceuticals Nasdaq: ORIC) is dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs.